Literature DB >> 8327657

Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters.

S J Knox1, W Sutherland, M L Goris.   

Abstract

The efficacy of exponentially decreasing low-dose-rate irradiation was compared with that of equivalent doses of multiply fractionated high-dose-rate external-beam irradiation in mice with three different kinds of tumors that varied in terms of alpha/beta ratio, tumor volume doubling times, and cell cycle times. Cell cycle distribution was measured after low-dose-rate and high-dose-rate irradiation. The relative efficacy of low-dose-rate irradiation versus equivalent doses of high-dose-rate irradiation was correlated with the extent of arrest of cells in G2 phase of the cell cycle. Unlike 38C13 murine B-cell lymphoma, neither the HT29 human colorectal xenograft or the SNB75 human glioblastoma xenograft was significantly more sensitive to low-dose-rate than fractionated high-dose-rate irradiation. The 38C13 B-cell lymphoma also had the shortest tumor volume doubling and cell cycle times, the most G2 arrest after low-dose-rate irradiation, more G2 arrest with low-dose-rate than high-dose-rate irradiation, and the highest alpha/beta ratio. The data presented here support the hypothesis that dose-rate effects may be minimal for tumors with small shoulders and large alpha/beta ratios and that arrest of cells in G2 phase plays an important role in cell death mediated by low-dose-rate irradiation. The proliferative rates of tumor cells may modify dose-rate effects further, and the interaction of all of these factors may explain in part the increased efficacy of low-dose-rate irradiation and radioimmunotherapy compared with high-dose-rate irradiation that has been reported in some animal models.

Entities:  

Mesh:

Year:  1993        PMID: 8327657

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

Review 1.  Stereotactic radiosurgery and interstitial brachytherapy for glial neoplasms.

Authors:  M W McDermott; M S Berger; Sandeep Kunwar; Andrew T Parsa; P K Sneed; David A Larson
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

2.  HRAD1 and MRAD1 encode mammalian homologues of the fission yeast rad1(+) cell cycle checkpoint control gene.

Authors:  C M Udell; S K Lee; S Davey
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

3.  Changes in cell cycle, apoptosis and necrosis following the establishment of a (125)I brachytherapy model in the spinal cord in Banna mini-pigs.

Authors:  Zuozhang Yang; Congguo Jin; Ting Chen; Hongpu Sun; Dakuan Yang; Yunchao Huang; Jin Zhang; Ruilian Zhao; Jinlei Zhang
Journal:  Oncol Lett       Date:  2011-11-17       Impact factor: 2.967

4.  Mild heat shock induces autophagic growth arrest, but not apoptosis in U251-MG and U87-MG human malignant glioma cells.

Authors:  Tadashi Komata; Takao Kanzawa; Takeo Nashimoto; Hiroshi Aoki; Shin Endo; Masaaki Nameta; Hideaki Takahashi; Tadashi Yamamoto; Seiji Kondo; Ryuichi Tanaka
Journal:  J Neurooncol       Date:  2004-06       Impact factor: 4.130

5.  131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma.

Authors:  Andrei Iagaru; Erik S Mittra; Kristen Ganjoo; Susan J Knox; Michael L Goris
Journal:  Mol Imaging Biol       Date:  2009-06-20       Impact factor: 3.488

Review 6.  Introduction to radiobiology of targeted radionuclide therapy.

Authors:  Jean-Pierre Pouget; Catherine Lozza; Emmanuel Deshayes; Vincent Boudousq; Isabelle Navarro-Teulon
Journal:  Front Med (Lausanne)       Date:  2015-03-17

Review 7.  Can high dose rates used in cancer radiotherapy change therapeutic effectiveness?

Authors:  Maria Konopacka; Jacek Rogoliński; Aleksander Sochanik; Krzysztof Ślosarek
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12

8.  Comparative study of Danshen and Siwu decoction based on the molecular structures of the components and predicted targets.

Authors:  Yang Li; Li Qiao; Cong Chen; Zhenguo Wang; Xianjun Fu
Journal:  BMC Complement Med Ther       Date:  2021-01-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.